STERIS Plc (Ireland) 10-Q 8 Nov 16 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information Document - shares	6 Months Ended
	Sep. 30, 2016	Nov. 02, 2016
Entity Information [Line Items]
Entity Registrant Name	STERIS plc
Entity Central Index Key	1,624,899
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--03-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		85,199,072

CONSOLIDATED BALANCE SHEETS (un

CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Sep. 30, 2016	Mar. 31, 2016
Current assets:
Cash and cash equivalents	$ 254,351	$ 248,841
Accounts receivable (net of allowances of $8,979 and $11,185 respectively)	441,294	471,523
Inventories, net	209,935	192,792
Prepaid expenses and other current assets	50,616	59,369
Total current assets	956,196	972,525
Property, plant, and equipment, net	1,039,783	1,064,319
Intangible Assets, Net (Including Goodwill)	3,181,463	3,279,942
Other assets	33,183	29,630
Total assets	5,210,625	5,346,416
Current liabilities:
Accounts payable	116,350	139,572
Accrued income taxes	16,278	13,683
Accrued payroll and other related liabilities	74,024	93,976
Accrued expenses and other	163,694	153,375
Total current liabilities	370,346	400,606
Long-term indebtedness	1,504,192	1,567,796
Deferred income taxes, net	247,713	254,824
Other Liabilities, Noncurrent	78,811	84,298
Total liabilities	2,201,062	2,307,524
Commitments and contingencies (see note 9
Preferred Stock, Value, Issued	15	15
Common shares, with GBP 0.10 par value; GBP 17,006 shares in the aggregate par amount authorized; 85,380 shares issued; and 85,920 shares outstanding	2,112,834	2,151,719
Retained earnings	979,711	939,459
Accumulated other comprehensive income	(94,028)	(68,159)
Total shareholders' equity	2,998,532	3,023,034
Noncontrolling interest	11,031	15,858
Total equity	3,009,563	3,038,892
Total liabilities and equity	$ 5,210,625	$ 5,346,416

CONSOLIDATED BALANCE SHEETS (u3

CONSOLIDATED BALANCE SHEETS (unaudited) Consolidated Balance Sheet (Parenthetical) £ in Thousands, $ in Thousands	Sep. 30, 2016GBP (£)£ / sharesshares	Sep. 30, 2016USD ($)shares	Mar. 31, 2016USD ($)$ / sharesshares
Allowance for Doubtful Accounts Receivable, Current | $		$ 8,979	$ 11,185
Preferred Stock, Shares Authorized	100,000	100,000	100,000
Preferred Stock, Shares Issued	100,000	100,000	100,000
Preferred Stock, Shares Outstanding	100,000	100,000	100,000
Preferred Stock, Par or Stated Value Per Share | (per share)	£ 0.10		$ 0.15
common stock aggregate par amount shares authorized | £	£ 17,006
Common Stock, Shares Authorized			170,060,000
Common Stock, Shares, Issued	85,380,000	85,380,000	85,920,000
Common Stock, Shares, Outstanding	85,380,000	85,380,000	85,920,000
Common Stock, Par or Stated Value Per Share | (per share)	£ 0.10		$ 0.15
Treasury Stock, Shares	0	0	0

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenues:
Product	$ 292,216	$ 274,145	$ 563,966	$ 506,452
Service	354,199	215,752	720,827	423,347
Total revenues	646,415	489,897	1,284,793	929,799
Cost of revenues:
Product	155,110	148,088	297,809	277,944
Service	243,397	132,488	499,086	258,444
Total cost of revenues	398,507	280,576	796,895	536,388
Gross Profit	247,908	209,321	487,898	393,411
Operating expenses:
Selling, general, and administrative	163,680	172,459	315,566	299,294
Research and development	14,617	14,255	29,045	28,020
Restructuring Costs	48	(56)	202	(782)
Total operating expenses	178,345	186,658	344,813	326,532
Income (loss) from operations	69,563	22,663	143,085	66,879
Non-operating expenses, net:
Interest expense	10,924	7,485	21,995	13,605
Interest income and miscellaneous expense	(284)	(227)	(778)	(709)
Total non-operating expenses, net	10,640	7,258	21,217	12,896
Income before income tax expense	58,923	15,405	121,868	53,983
Income tax expense	(18,721)	(7,154)	(32,955)	(21,421)
Net Income	40,202	8,251	88,913	32,562
Net Income (Loss) Attributable to Noncontrolling Interest	(214)	(436)	95	(416)
Net income attributable to shareholders	$ 40,416	$ 8,687	$ 88,818	$ 32,978
Net income (loss) per common share
Basic	$ 0.47	$ 0.15	$ 1.03	$ 0.55
Diluted	0.47	0.14	1.03	0.55
Cash dividends declared per common share outstanding	$ 0.28	$ 0.25	$ 0.53	$ 0.48

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Net Income	$ 40,202	$ 8,251	$ 88,913	$ 32,562
Net Income (Loss) Attributable to Noncontrolling Interest	(214)	(436)	95	(416)
Net income attributable to shareholders	40,416	8,687	88,818	32,978
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	26	(552)	(94)	(1,400)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Unamortized Gain (Loss) Arising During Period, Net of Tax	(390)	(227)	(780)	(380)
Other Comprehensive Income (Loss), Finalization of Pension and Other Postretirement Benefit Plan Valuation, Net of Tax	0	17,029	0	17,029
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	(7,946)	(21,841)	(24,995)	(8,043)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(8,310)	(5,591)	(25,869)	7,206
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	31,583	3,096	62,949	40,184
Other Comprehensive Income (Loss), Available-for-sale Securities, Tax	80	(46)	114	(263)
Other Comprehensive (Income) Loss, Amortization Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax	242	95	482	189
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Tax	$ 0	$ 10,563	$ 0	$ 10,563

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)	6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Net income attributable to shareholders	$ 88,818,000	$ 32,978,000
Net Income	88,913,000	32,562,000
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation, depletion, and amortization	103,861,000	46,098,000
Deferred income taxes	(4,606,000)	(8,903,000)
Share-based compensation	10,564,000	7,865,000
Pension Expense	0	26,515,000
Pension Contributions	0	(4,687,000)
Loss on the disposal of property, plant, equipment, and intangibles, net	281,000	103,000
Excess Tax Benefit from Share-based Compensation, Operating Activities	0	(4,676,000)
Gain (Loss) on Disposition of Business	13,802,000	0
Other items	5,696,000	2,692,000
Changes in operating assets and liabilities:
Accounts receivable, net	11,671,000	31,621,000
Inventories, net	(21,723,000)	(19,986,000)
Other current assets	6,216,000	(675,000)
Accounts payable	(16,954,000)	(17,325,000)
Accruals and other, net	(9,221,000)	(11,732,000)
Net cash provided by operating activities	188,501,000	79,472,000
Investing activities:
Purchases of property, plant, equipment, and intangibles, net	(73,866,000)	(39,928,000)
Proceeds from the sale of property, plant, equipment, and intangibles	4,763,000	38,000
Proceeds from Divestiture of Businesses	131,586,000	0
Payments to Acquire Investments	(6,356,000)	0
Other Payments to Acquire Businesses	(64,872,000)	(220,840,000)
Net cash used in investing activities	(8,745,000)	(260,730,000)
Financing activities:
Proceeds from Issuance of Private Placement	0	350,000,000
Repayments of Long-term Debt	(10,000,000)	0
Proceeds Under Credit Facility, net	(47,646,000)	(139,750,000)
Payments of Financing Costs	0	(2,426,000)
Payments of Merger Related Costs, Financing Activities	(6,000,000)	0
Repurchases of common shares	(59,895,000)	(12,974,000)
Cash dividends paid to common shareholders	(45,585,000)	(28,740,000)
Proceeds from Issuance or Sale of Equity	5,022,000	0
Stock option and other equity transactions, net	2,494,000	8,111,000
Excess Tax Benefit from Share-based Compensation, Financing Activities	0	4,676,000
Net cash used in financing activities	(161,610,000)	178,897,000
Effect of exchange rate changes on cash and cash equivalents	(12,636,000)	(3,141,000)
(Decrease) increase in cash and cash equivalents	5,510,000	(5,502,000)
Cash and cash equivalents at beginning of period	248,841,000	167,689,000
Cash and cash equivalents at end of period	$ 254,351,000	$ 162,187,000

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	6 Months Ended
	Sep. 30, 2016
Notes To Financial Statements [Abstract]
Nature of Operations [Text Block]	Nature of Operations and Summary of Significant Accounting Policies Nature of Operations STERIS plc, a public limited company organized under the laws of England and Wales, was incorporated on October 9, 2014 as a private limited company and was re-registered effective November 2, 2015 as a public limited company under the name STERIS plc. New STERIS Limited was established to effect the combination (“Combination”) of STERIS Corporation, an Ohio corporation (“Old STERIS”), and Synergy Health plc, a public limited company organized under the laws of England and Wales (“Synergy”). The Combination closed on November 2, 2015 and as a result STERIS plc became the ultimate parent company of Old STERIS and Synergy. Synergy has been re-registered under the name Synergy Health Limited. The acquisition of Old STERIS was accounted for in the consolidated financial statements as a merger between entities under common control; accordingly the historical consolidated financial statements of Old STERIS for periods prior to November 2, 2015, are considered to be the historical financial statements of STERIS plc. Due to the timing of the Combination, the results of Synergy are only reflected in the results of operations of the Company from November 2, 2015 forward which affects comparability to the prior period historical operations of the Company throughout this Quarterly Report on Form 10-Q. STERIS offers Customers capital equipment products, such as sterilizers and surgical tables; connectivity solutions such as operating room integration; consumable products, such as detergents, gastrointestinal endoscopy accessories, barrier product solutions, and other products and services, including: equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair solutions, among other services. Our fiscal year ends on March 31. References in this Quarterly Report to a particular “year” or “year-end” mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below: Interim Financial Statements We prepared the accompanying unaudited consolidated financial statements of the Company according to accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. This means that they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our unaudited interim consolidated financial statements contain all material adjustments (including normal recurring accruals and adjustments) management believes are necessary to fairly state our financial condition, results of operations, and cash flows for the periods presented. These interim consolidated financial statements should be read together with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended March 31, 2016 dated May 31, 2016 . The Consolidated Balance Sheet at March 31, 2016 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Principles of Consolidation We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements. Use of Estimates We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three and six month periods ended September 30, 2016 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2017 . Recently Issued Accounting Standards Impacting the Company Recently issued accounting standards impacting the Company are presented in the following table: Standard Date of Issuance Description Date of Adoption Effect on the financial statements or other significant matters Standards that have recently been adopted ASU 2015-05, "Goodwill and other-Internal-Use Software" (Subtopic 350-40) April 2015 The standard provides guidance on a customer's accounting for fees paid in cloud computing arrangements. Previously, there was no U.S. GAAP guidance on accounting for such fees from the customer's perspective. Under the standard, customers will apply the same criteria as vendors to determine whether the arrangement contains a software license or is solely a service contract. The determination could impact the classification of advance payments in the statements of financial position and cash flows as well as the classification of the expenses in the results of operations. The standard is effective for annual periods beginning after December 15, 2015 and interim periods within that period. Early adoption is permitted. First Quarter Fiscal 2017 The adoption of this standard did not have a material impact on our statements of consolidated financial position, results of operations and cash flows. ASU 2016-09, "Stock Compensation: Improvements to Employee Share-Based Payment Accounting" (Topic 718) March 2016 The update simplifies several aspects of the accounting for share-based payment award transactions, including income tax consequences, the classification of awards as either equity or liabilities, and the classification on the statement of cash flows. The standard is effective for annual periods beginning after December 15, 2016 and interim periods within that period. Early adoption is permitted. First Quarter Fiscal 2017 As a result of the adoption of this standard, we recorded $3.5 million of excess tax benefits associated with share based compensation in the statement of income for the six months ended September 30, 2016 and have included the associated cash flows as cash provided by operating activities. Prior periods have not been restated. Standards that have yet to be adopted ASU 2014-09, "Revenue from Contracts with Customers" May 2014 The standard will replace existing revenue recognition standards and significantly expand the disclosure requirements for revenue arrangements. It may be adopted either retrospectively or on a modified retrospective basis to new contracts and existing contracts with remaining performance obligations as of the effective date. The standard update is effective for annual periods beginning after December 15, 2017 and interim periods within that period, early adoption is not permitted before the original public entity effective date of December 15, 2016. N/A We are currently in the process of evaluating the impact that the standard will have on our consolidated financial position, results of operations and cash flows. ASU 2016-02, "Leases" (Topic 842) February 2016 The update will require lessees to record all leases, whether finance or operating, on the balance sheet. An asset will be recorded to represent the right to use the leased asset, and a liability will be recorded to represent the lease obligation. The standard is effective for annual periods beginning after December 15, 2018 and interim periods within that period. Early adoption is permitted. N/A We are in the process of evaluating the impact that the standard will have on our statements of consolidated financial position, results of operations and cash flows. ASU 2016-07, "Investments - Equity Method and Joint Ventures, Simplifying the Transition to the Equity Method of Accounting" (Topic 323) March 2016 The update replaces the previous requirement to retroactively adopt the equity method. The new standard requires that the equity method investor add the cost of acquiring the additional interest in the investee to the current basis of the investor's previously held interest and adopt the equity method of accounting as of the date the investment becomes qualified for equity method accounting. The standard is effective for annual periods beginning after December 15, 2016 and interim periods within that period. Early adoption is permitted. N/A We do not expect the adoption of this standard to have a material impact on our statements of consolidated financial position, results of operations and cash flows. ASU 2016-15, "Statement of Cash Flows" (Topic 230) August 2016 This update provides guidance on the following several specific cash flow issues: Debt prepayment or debt extinguishment costs, Settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies, distributions received from equity method investees, beneficial interests in securitization transactions, and separately identifiable cash flows and application of the predominance principle. The standard is effective for annual periods beginning after December 15, 2017 and interim periods within that period. Early adoption is permitted. N/A We are in the process of evaluating the impact that the standard will have on our statement of cash flows. A detailed description of our significant and critical accounting policies, estimates, and assumptions is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2016 dated May 31, 2016 . Our significant and critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2016 .

Business Acquisitions and Dives

Business Acquisitions and Divestitures (Notes)	6 Months Ended
	Sep. 30, 2016
Business Acquisitions and Divestitures [Abstract]
Business Combination Disclosure [Text Block]	2. Business Acquisitions and Divestitures Fiscal 2017 Acquisitions Compass Medical Inc On September 16, 2016, we purchased the assets of Compass Medical, Inc., for approximately $16.0 million . The purchase price was financed with credit facility borrowings. Compass Medical, Inc. specializes in the sale and repair of flexible endoscopes. On an annual basis, Compass Medical, Inc. has generated revenues of approximately $6.0 million and will be integrated into our Healthcare Specialty Services segment. Phoenix Surgical Holdings, Ltd. and Endo-Tek LLP On August 31, 2016, we purchased 100% of the shares of Phoenix Surgical Holdings, Ltd. and the assets of Endo-Tek LLP for approximately $14.3 million combined. The purchase price was financed with cash on hand. On an annual basis, these operations, which specialize in the repair of endoscopes, generated approximately $8.0 million in combined revenue and will be integrated into our Healthcare Specialty Services segment. Medisafe On July 22, 2016, we purchased 100% of the shares of Medisafe Holdings, Ltd., a U.K. manufacturer of washer/disinfector equipment and related consumables and services for approximately $34.3 million . The purchase price was financed with cash on hand. On an annual basis, the Medisafe product line has generated approximately $18.0 million in revenue. The acquisition of Medisafe provides washer manufacturing and research and development capabilities in the U.K. Medisafe's products and services will be integrated into our Healthcare Products segment. Fiscal 2016 Acquisitions Synergy Health plc On November 2, 2015, STERIS acquired all outstanding shares of Synergy in a cash and stock transaction valued at £24.80 ( $38.17 ) per Synergy share, or a total of approximately $2.3 billion based on the low trading price of Old STERIS’s stock of $73.02 per share on November 2, 2015. The Combination brought together businesses that generate revenues from over 100 countries, employ approximately 14,000 employees, and are geographically complementary. The Combination is expected to result in cost savings from optimizing global back-office infrastructure, leveraging best-demonstrated practices across plants, in-sourcing consumables, and eliminating redundant public company costs. Total costs of approximately $63,789 before tax, were incurred during fiscal year 2016 related to the Combination and are reported in selling, general and administrative expense. The acquisition of Synergy has been accounted for using the acquisition method of accounting which requires, among other things, the assets acquired, liabilities assumed and noncontrolling interests be recognized at their respective fair values as of the acquisition date. Acquisition accounting is dependent upon certain valuations and other studies that are in progress and are not yet to a stage where there is sufficient information for a definitive measurement. The process for estimating the fair values of identifiable intangible assets and certain tangible assets and assumed liabilities requires the use of judgment in determining the appropriate assumptions and estimates. The purchase price allocation for Synergy is preliminary. We will finalize the fair values of assets acquired, liabilities assumed, and noncontrolling interests in the third quarter of fiscal 2017, and additional purchase price adjustments will be recorded. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact our results of operations. The finalization of the purchase accounting assessment will result in changes in the valuation of assets acquired and liabilities assumed and may have a material impact on the our results of operations and financial position. Goodwill will be allocated to the Healthcare Products, Healthcare Specialty Services, and Applied Sterilization Technologies segments. Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected revenue and cost synergies of the combined company and assembled workforce, which are further described above. Goodwill recognized as a result of the acquisition is not deductible for tax purposes. The Consolidated Financial Statements include the operating results of acquisitions from the acquisition dates. The table below summarizes the preliminary allocation of the purchase price to the net assets acquired based on fair values at the acquisition date. Fiscal Year 2017 (1) Fiscal Year 2016 (1) Medisafe Compass Phoenix and Endo-Tek Synergy Cash $ 3,767 $ — $ 769 $ 53,057 Accounts receivable 3,703 262 1,123 107,341 Inventory 2,500 834 950 30,074 Property, plant and equipment 642 283 1,092 534,879 Other assets — 445 46 19,708 Intangible assets 12,239 5,826 — 806,526 Goodwill 20,706 8,739 12,794 1,411,781 Total Assets 43,557 16,389 16,774 2,963,366 Current liabilities (5,281 ) (387 ) (1,373 ) (108,192 ) Long-term indebtedness — — — (321,082 ) Non-current liabilities (227 ) — (295 ) (230,544 ) Total Liabilities (5,508 ) (387 ) (1,668 ) (659,818 ) Net Assets $ 38,049 $ 16,002 $ 15,106 $ 2,303,548 (1) Purchase price allocation are still preliminary as of September 30, 2016, as valuations have not been finalized. Divestitures Applied Infection Control We completed the sale of our Applied Infection Control ("AIC") product line to DEB USA, Inc., a wholly-owned subsidiary of S.C Johnson & Son, Inc. Annual revenues for the AIC product line were typically less than $50 million and were included in the Healthcare Products segment. We recorded proceeds of $41.8 million and recognized a pre-tax gain on the sale of $35.0 million during the second quarter of 2017 in Selling, General, and Administrative Expense in the Consolidated Statement of Income. UK Linen Management Services We sold our UK Linen Management Services business to STAR Mayan Limited. Annual revenues for the UK Linen Management Services were approximately $50 million and were included in the Healthcare Specialty Services segment. We recorded proceeds of $65.0 million and recognized a pre-tax loss on the sale of $65.4 million after allocation of a portion of the identified intangibles and goodwill associated with the Combination with Synergy during the second quarter of 2017 in Selling, General, and Administrative Expense in the Consolidated Statement of Income. Synergy Health Labs We sold Synergy Health Laboratory Services to SYNLAB International. Annual revenues for the Synergy Health Labs were approximately $15 million and were included in the Applied Sterilization Technologies segment. We recorded proceeds of $24.9 million and recognized a pre-tax gain on the sale of $16.5 million during the second quarter of 2017 in Selling, General, and Administrative Expense in the Consolidated Statement of Income.

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment	Property, Plant and Equipment Information related to the major categories of our depreciable assets is as follows: September 30, March 31, Land and land improvements (1) $ 38,995 $ 39,051 Buildings and leasehold improvements 445,124 446,277 Machinery and equipment 550,003 580,962 Linens 30,234 42,354 Information systems 132,140 126,180 Radioisotope 441,582 434,152 Construction in progress (1) 100,158 79,291 Total property, plant, and equipment 1,738,236 1,748,267 Less: accumulated depreciation and depletion (698,453 ) (683,948 ) Property, plant, and equipment, net $ 1,039,783 $ 1,064,319 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service.

Inventories, Net

Inventories, Net	6 Months Ended
	Sep. 30, 2016
Notes To Financial Statements [Abstract]
Inventories, Net	Inventories, Net Inventories, net are stated at the lower of cost or market. We use the last-in, first-out (“LIFO”) and first-in, first-out cost methods. An actual valuation of inventory under the LIFO method is made only at the end of the fiscal year based on the inventory levels and costs at that time. Accordingly, interim LIFO calculations are based on management’s estimates of expected year-end inventory levels and are subject to the final fiscal year-end LIFO inventory valuation. Inventory costs include material, labor, and overhead. Inventories, net consisted of the following: September 30, March 31, Raw materials $ 68,476 $ 62,673 Work in process 23,481 19,614 Finished goods 153,902 146,820 LIFO reserve (17,299 ) (17,608 ) Reserve for excess and obsolete inventory (18,625 ) (18,707 ) Inventories, net $ 209,935 $ 192,792

Debt

Debt	6 Months Ended
	Sep. 30, 2016
Notes To Financial Statements [Abstract]
Debt	Debt Indebtedness was as follows: September 30, March 31, Private Placement $ 666,000 $ 666,000 Deferred financing costs (3,178 ) (3,420 ) Credit Agreement 841,370 905,216 Total long term debt $ 1,504,192 $ 1,567,796 Additional information regarding our indebtedness is included in the notes to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2016 dated May 31, 2016 .

Additional Consolidated Balance

Additional Consolidated Balance Sheets Information	6 Months Ended
	Sep. 30, 2016
Notes To Financial Statements [Abstract]
Additional Consolidated Balance Sheets Information	Additional Consolidated Balance Sheet Information Additional information related to our Consolidated Balance Sheets is as follows: September 30, March 31, Accrued payroll and other related liabilities: Compensation and related items $ 34,801 $ 30,175 Accrued vacation/paid time off 11,193 14,368 Accrued bonuses 12,892 31,502 Accrued employee commissions 11,826 13,809 Other postretirement benefit obligations-current portion 2,463 2,463 Other employee benefit plans obligations-current portion 849 1,659 Total accrued payroll and other related liabilities $ 74,024 $ 93,976 Accrued expenses and other: Deferred revenues $ 66,792 $ 56,238 Self-insured risk reserves-current portion 9,120 8,266 Accrued dealer commissions 14,070 12,717 Accrued warranty 6,466 5,909 Other 67,246 70,245 Total accrued expenses and other $ 163,694 $ 153,375 Other liabilities: Self-insured risk reserves-long-term portion $ 13,257 $ 13,257 Other postretirement benefit obligations-long-term portion 15,103 15,932 Defined benefit pension plans obligations-long-term portion 21,927 25,301 Other employee benefit plans obligations-long-term portion 4,063 4,366 Accrued long-term income taxes 3,779 — Asset retirement obligation-long-term portion 10,033 10,342 Other 10,649 15,100 Total other liabilities $ 78,811 $ 84,298

Income Tax Expense (Benefit)

Income Tax Expense (Benefit)	6 Months Ended
	Sep. 30, 2016
Notes To Financial Statements [Abstract]
Income Tax Expense (Benefit)	Income Tax Expense The effective income tax rate for continuing operations for the three month period ended September 30, 2016 was 31.8% compared with 46.4% for the same prior year period. The effective income tax rates for the six month periods ended September 30, 2016 and 2015 were 27.0% and 39.7% , respectively. The fiscal 2017 rates were favorably impacted by benefits achieved in conjunction with the Combination with Synergy, the adoption of ASU 2016-09: "Stock Compensation: Improvements to Employee Share-Based Payment Accounting" (Topic 718), and discrete item adjustments related to future tax rate changes in the United Kingdom. Income tax expense is provided on an interim basis based upon our estimate of the annual effective income tax rate, adjusted each quarter for discrete items. In determining the estimated annual effective income tax rate, we analyze various factors, including projections of our annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, our ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives. We operate in numerous taxing jurisdictions and are subject to regular examinations by various United States federal, state and local authorities, as well as foreign jurisdictions. We are no longer subject to United States federal examinations for years before fiscal 2013 and, with limited exceptions, we are no longer subject to United States state and local or non-United States income tax examinations by tax authorities for years before fiscal 2012. We remain subject to tax authority audits in various jurisdictions wherever we do business. We do not expect the results of these examinations to have a material adverse affect on our consolidated financial statements.

Benefit Plans

Benefit Plans	6 Months Ended
	Sep. 30, 2016
Notes To Financial Statements [Abstract]
Benefit Plans	Benefit Plans In the United States we sponsor an unfunded postretirement welfare benefits plan for two groups of former employees. Benefits under this plan include retiree life insurance and retiree medical coverage, including prescription drug coverage. During the second quarter of fiscal 2009, we amended our United States post-retirement welfare benefits plan, reducing the benefits to be provided to retirees under the plan and increasing their share of the costs. The amendments resulted in a decrease of $46,001 in the accumulated post-retirement benefit obligation. The impact of this change was recognized in our Consolidated Balance Sheets in fiscal 2009 and is being amortized as a component of the annual net periodic benefit cost over a period of approximately thirteen years. In July 2014, the Board of Directors of American Sterilizer Company (“AMSCO”) approved the termination of the American Sterilizer Company Retirement Income Plan (“Plan”) effective October 1, 2014. The Pension Benefit Guaranty Corporation ("PBGC") did not object to this termination and AMSCO received a favorable determination from the IRS regarding the termination. On August 19, 2015, an annuity contract was purchased from Massachusetts Mutual Life Insurance Company to provide Plan benefits. Plan assets were converted to cash to fund the purchase. The purchase price of the annuity contract was $51,805 . An additional employer contribution of $4,641 was made to the Plan to fund the annuity purchase obligation on August 26, 2015. As a result the purchase of the annuity, we recognized a pension settlement of $26,470 in fiscal 2016. In addition, plan benefits and benefit administration became the responsibility of the annuity provider. Additional information regarding this defined benefit pension plan and other postretirement benefits plan is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2016, dated May 31, 2016. In the United Kingdom, we sponsor a defined benefit arrangement administered by a single group of trustees. The arrangement is comprised of three merged schemes. The trustees hold the pension assets to meet long-term pension liabilities for past and present employees. The level of retirement benefit is principally based on the terms of the scheme and the final pensionable salary prior to leaving active service, and is linked to changes in inflation up to retirement. In previous years, Synergy sponsored a funded defined benefit arrangement in the Netherlands. This was a separate fund holding the pension scheme assets to meet long term pension liabilities for past and present employees. Accrual of benefits ceased under the scheme effective January 1, 2013. The Synergy Radeberg and Synergy Allershausen Schemes are German defined benefit funded pension schemes which are closed to new entrants. The Synergy Daniken Scheme is a Swiss defined benefit funded pension scheme. Components of the net periodic benefit cost for our defined benefit pension plans and other postretirement medical benefits plan were as follows: AMSCO Plan Other Defined Benefit Pension Plan Other Postretirement Benefits Plan Three Months Ended September 30, 2016 2015 2016 2015 2016 2015 Service cost $ — $ 11 $ 472 $ — $ — $ — Interest cost — 224 189 — 139 148 Expected return on plan assets — (403 ) — — — — Amortization of loss — 241 — — 184 207 Settlement — 26,470 — — — — Amortization of prior service cost — — — — (816 ) (815 ) Net periodic benefit cost $ — $ 26,543 $ 661 $ — $ (493 ) $ (460 ) AMSCO Plan Other Defined Benefit Pension Plan Other Postretirement Benefits Plan Six Months Ended September 30, 2016 2015 2016 2015 2016 2015 Service cost $ — $ 27 $ 944 $ — $ — $ — Interest cost — 560 378 — 277 296 Expected return on plan assets — (1,008 ) — — — — Amortization of loss — 602 — — 369 414 Settlement — 26,470 — — — — Amortization of prior service cost — — — — (1,631 ) (1,631 ) Net periodic benefit cost $ — $ 26,651 $ 1,322 $ — $ (985 ) $ (921 ) We contribute amounts to the defined benefit pension plans at least sufficient to meet the minimum requirements as stated in applicable employee benefit laws and local tax laws. We record liabilities for the difference between the fair value of the plan assets and the benefit obligation (the projected benefit obligation for pension plan and the accumulated postretirement benefit obligation for other postretirement benefits plan) on our accompanying Consolidated Balance Sheets. Finally, the Dutch linen business acquired in the Synergy combination participates in a multi-employer industry-wide defined benefit scheme. Participation in this pension plan is mandatory. The pension scheme is an average pay scheme with a conditional fee (indexation). Indexation of assets and liabilities granted under the pension scheme takes place only if and insofar as the resources of the fund allow for it and this decision is taken by the pension fund. The pension entitlements under the pension plan are fully reinsured. It is not possible to identify the share of the underlying assets, liabilities, and overall surplus/deficit of the scheme attributable to the business, because the scheme is industry-wide. Under the guidance provided in ASC 715, "Compensation-Retirement Benefits", the scheme is treated as a defined contribution scheme within our financial statements. The total cost charged to the income statement in respect to this scheme was $1,322 for the six months ended September 30, 2016.

Contingencies

Contingencies	6 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Loss Contingencies by Contingency [Text Block]	Commitments and Contingencies We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief. We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse effect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations, claims or other proceedings (including without limitation the matters discussed below). For certain types of claims, we presently maintain insurance coverage for personal injury and property damage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us. On May 31, 2012, our Albert Browne Limited subsidiary received a warning letter from the FDA regarding chemical indicators manufactured in the United Kingdom. These devices are intended for the monitoring of certain sterilization and other processes. The FDA warning letter states that the agency has concerns regarding operational business processes. We do not believe that the FDA's concerns are related to product performance, or that they result from Customer complaints. We have reviewed our processes with the agency and finalized our remediation measures, and are awaiting FDA reinspection. We do not currently believe that the impact of this event will have a material adverse effect on our financial results. On December 19, 2014, a purported shareholder of Old STERIS filed a Verified Stockholder Derivative Complaint in the Court of Common Pleas, Cuyahoga County, Ohio (the "Court"), against the members of Old STERIS’s board of directors and certain officers of Old STERIS, challenging the excise tax make-whole payments approved by Old STERIS’s board in connection with the Combination. Old STERIS was named as a nominal defendant in the action. The case is captioned St. Lucie County Fire District Firefighters’ Pension Trust Fund v. Rosebrough, Jr., et al. , Case No. CV 14 837749 (the "Action"). On September 28, 2015, the defendants reached an agreement in principle with plaintiff, regarding a settlement of the Action, and that agreement is reflected in a memorandum of understanding. In connection with the contemplated settlement, Old STERIS agreed to make certain additional disclosures related to the make-whole payments, which disclosures were reported on Old STERIS's Form 8-K dated September 28, 2015, and also agreed not to grant any new stock compensation subject to Section 4985 of the Internal Revenue Code to any of the individual defendants in the Action until six months following the closing date of the Combination. The parties have subsequently entered into and executed a stipulation of settlement, on a combined class and derivative basis, including agreement on a maximum fee/expense award to plaintiff's counsel. The stipulation of settlement, which is subject to customary conditions including approval of the Court following notice and hearing, has been filed with the Court along with a request for preliminary approval and the setting of a hearing date. A hearing on this matter has been scheduled by the Court for November 10, 2016. There can be no assurance that the Court will approve the proposed settlement and the settlement agreement may be terminated if Court approval is not obtained. Other civil, criminal, regulatory or other proceedings involving our products or services could possibly result in judgments, settlements or administrative or judicial decrees requiring us, among other actions, to pay damages or fines or effect recalls, or be subject to other governmental, Customer or other third party claims or remedies, which could materially effect our business, performance, prospects, value, financial condition, and results of operations. For additional information regarding these matters, see the following portions of our Annual Report on Form 10-K for the year ended March 31, 2016 dated May 31, 2016: “Business - Information with respect to our Business in General - Government Regulation”, and the “Risk Factor” titled “We may be adversely affected by product liability claims or other legal actions or regulatory or compliance matters. From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized. We are subject to taxation from United States federal, state and local, and foreign jurisdictions. Tax positions are settled primarily through the completion of audits within each individual jurisdiction or the closing of statutes of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. We describe income taxes further in note 7 to our consolidated financial statements titled, “Income Tax Expense” in this Quarterly Report on Form 10-Q. Additional information regarding our contingencies is included in Item 2 titled, “Management’s Discussion and Analysis of Financial Conditions and Results of Operations under "Contingencies".

Business Segment Information

Business Segment Information	6 Months Ended
	Sep. 30, 2016
Notes To Financial Statements [Abstract]
Business Segment Information	Business Segment Information We operate and report in four reportable business segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. Corporate and other, which is presented separately, contains the Defense and Industrial business unit plus costs that are associated with being a publicly traded company and certain other corporate costs. Our Healthcare Products segment offers infection prevention and procedural solutions for healthcare providers worldwide, including capital equipment and related maintenance and installation services, as well as consumables. Our Healthcare Specialty Services segment provides a range of specialty services for healthcare providers including hospital sterilization services, instrument and scope repairs, and linen management. Our Life Sciences segment offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities. Our Applied Sterilization Technologies segment offers contract sterilization and laboratory services for medical device and pharmaceutical Customers and others. The accounting policies for reportable segments are the same as those for the consolidated Company. Management evaluates performance and allocates resources based on a segment operating income measure. Operating income (loss) for each segment is calculated as the segment’s gross profit less direct expenses and indirect cost allocations, which result in the full allocation of all distribution and research and development expenses, and the partial allocation of corporate costs. These allocations are based upon variables such as segment headcount and revenues. In addition, the Healthcare Products segment is responsible for the management of all but two manufacturing facilities and uses standard cost to sell products to the other segments. Corporate and other includes the gross profit and direct expenses of the Defense and Industrial business unit, as well as certain unallocated corporate costs related to being a publicly traded company and legacy pension and post-retirement benefits. Segment operating income excludes certain adjustments which include acquisition and integration related costs, amortization of acquired intangibles, gains or losses on divestiture of businesses, restructuring costs and other charges that management believes may or may not recur with similar materiality or impact on operating income in future periods. Management believes that by excluding these items they gain better insight and greater transparency of the operating performance of the segments, thus aiding them in more meaningful financial trend analysis and operational decision making For the three and six month periods ended September 30, 2016 , revenues from a single Customer did not represent ten percent or more of any reportable segment’s revenues. Additional information regarding our segments is included in our consolidated financial statements included in its Annual Report on Form 10-K for the year ended March 31, 2016 , dated May 31, 2016 . Financial information for each of our segments is presented in the following tables: Three Months Ended September 30, Six Months Ended September 30, 2016 2015 2016 2015 Revenues: Healthcare Products $ 304,797 $ 291,724 $ 586,095 $ 552,809 Healthcare Specialty Services 142,775 70,565 300,663 138,807 Life Sciences 81,485 71,040 162,674 127,812 Applied Sterilization Technologies 115,601 55,839 232,174 109,528 Corporate and other 1,757 729 3,187 843 Total revenues $ 646,415 $ 489,897 $ 1,284,793 $ 929,799 Segment operating income: Healthcare Products $ 50,098 $ 40,414 $ 84,737 $ 69,764 Healthcare Specialty Services 2,175 5,092 5,493 8,992 Life Sciences 22,772 20,883 47,234 34,333 Applied Sterilization Technologies 40,761 17,493 80,364 34,036 Corporate and other (4,741 ) (4,034 ) (5,237 ) (5,932 ) Total segment operating income $ 111,065 $ 79,848 $ 212,591 $ 141,193 Less: Adjustments Restructuring charges (1) $ 48 $ (15 ) $ 202 $ (464 ) Amortization of acquired intangible assets (2) 17,779 6,682 37,308 12,703 Acquisition and integration related charges (3) 6,638 23,982 11,873 35,528 Loss on fair value adjustment of acquisition related contingent consideration 1,850 — 1,850 — Net loss on divestiture of businesses (2) 13,802 — 13,802 — Amortization of inventory and property "step up" to fair value (2) 1,385 21 4,471 32 Settlement of pension obligation (4) — 26,515 — 26,515 Total operating income $ 69,563 $ 22,663 $ 143,085 $ 66,879

Common Shares

Common Shares	6 Months Ended
	Sep. 30, 2016
Notes To Financial Statements [Abstract]
Earnings Per Share [Text Block]	We calculate basic earnings per share based upon the weighted average number of shares outstanding. We calculate diluted earnings per share based upon the weighted average number of shares outstanding plus the dilutive effect of share equivalents calculated using the treasury stock method. The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share: Three Months Ended September 30, Six Months Ended September 30, 2016 2015 2016 2015 Denominator (shares in thousands): Weighted average shares outstanding—basic 85,851 59,897 85,944 59,832 Dilutive effect of share equivalents 482 473 482 496 Weighted average shares outstanding and share equivalents—diluted 86,333 60,370 86,426 60,328 Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive: Three Months Ended September 30, Six Months Ended September 30, 2016 2015 2016 2015 (shares in thousands) Number of share options 627 419 496 235 Preferred Shares Pursuant to an engagement letter dated October 23, 2015, we issued 100,000 preferred shares, par value of £0.10 ( $0.15 ) each, for an aggregate consideration of approximately $15 , in satisfaction of debt owed to a service provider. The holders of the preferred shares are entitled to a fixed cumulative preferential annual dividend of 5 percent on the amount paid periodically on the preferred shares respectively held by them. On a return of capital of the Company whether on liquidation or otherwise, the holders of the preferred shares shall be entitled to receive out of the assets of the Company available for distribution to its shareholders the sum of £0.10 ( $0.15 ) per preferred share plus any accrued but unpaid dividend, but will not be entitled to any further participation in the assets of the Company. The holders of the preferred shares will have no right to attend, speak or vote, whether in person or by proxy, at any general meeting of the Company or any meeting of a class of members of the Company in respect of the preferred shares and will not be entitled to receive any notice of meetings.

Repurchases of Common Shares

Repurchases of Common Shares	6 Months Ended
	Sep. 30, 2016
Notes To Financial Statements [Abstract]
Schedule of Treasury Stock by Class [Text Block]	Repurchases of Shares On August 9, 2016, the Company announced that its Board of Directors had authorized the purchase of up to $300 million of our ordinary shares. We may enter into share repurchase contracts until August 2, 2021 to effect these purchases. Shares may be repurchased from time to time through open market transactions, including 10b5-1 plans. The repurchase program may be suspended or discontinued at any time. During the first half of fiscal 2017, we repurchased 819,105 of our ordinary shares pursuant to this authorization, all of which were repurchased in the second quarter. During the first half of fiscal 2017, we obtained 127,520 of our ordinary shares in connection with share based compensation award programs.

Share-Based Compensation

Share-Based Compensation	6 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	Share-Based Compensation We maintain a long-term incentive plan that makes available shares for grants, at the discretion of the Compensation Committee of the Board of Directors, to officers, directors, and key employees in the form of stock options, restricted shares, restricted share units, stock appreciation rights and share grants. Stock options provide the right to purchase our shares at the market price on the date of grant, subject to the terms of the option plans and agreements. Generally, one-fourth of the stock options granted become exercisable for each full year of employment following the grant date. Stock options granted generally expire 10 years after the grant date, or in some cases earlier if the option holder is no longer employed by us. Restricted shares and restricted share units generally may cliff vest after a four year period or vest in tranches of one-fourth of the number granted for each full year of employment after the grant date. As of September 30, 2016 , 5,588,018 shares remained available for grant under the long-term incentive plan. On November 8, 2016, we filed a Form S-8 to register an additional 4,031,196 shares to be made available for equity awards under the long-term incentive plan. The fair value of share-based compensation awards was estimated at their grant date using the Black-Scholes-Merton option pricing model. This model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable, characteristics that are not present in our option grants. If the model permitted consideration of the unique characteristics of employee stock options, the resulting estimate of the fair value of the stock options could be different. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our Consolidated Statements of Income. The expense is classified as cost of goods sold or selling, general and administrative expenses in a manner consistent with the employee’s compensation and benefits. The following weighted-average assumptions were used for options granted during the first half of fiscal 2017 and 2016 : Fiscal 2017 Fiscal 2016 Risk-free interest rate 1.29 % 1.51 % Expected life of options 5.66 years 5.69 years Expected dividend yield of stock 1.54 % 1.40 % Expected volatility of stock 22.92 % 25.06 % The risk-free interest rate is based upon the U.S. Treasury yield curve. The expected life of options is reflective of historical experience, vesting schedules and contractual terms. The expected dividend yield of stock represents our best estimate of the expected future dividend yield. The expected volatility of stock is derived by referring to our historical stock prices over a time frame similar to that of the expected life of the grant. An estimated forfeiture rate of 1.85% and 1.55% was applied in fiscal 2017 and 2016 , respectively. This rate is calculated based upon historical activity and represents an estimate of the granted options not expected to vest. If actual forfeitures differ from this calculated rate, we may be required to make additional adjustments to compensation expense in future periods. The assumptions used above are reviewed at the time of each significant option grant, or at least annually. A summary of share option activity is as follows: Number of Options Weighted Average Exercise Price Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at March 31, 2016 1,729,517 $ 44.01 Granted 402,141 69.85 Exercised (81,539 ) 29.44 Forfeited (9,226 ) 64.43 Canceled (470 ) 25.98 Outstanding at September 30, 2016 2,040,423 $ 49.59 6.7 years $ 47,968 Exercisable at September 30, 2016 1,206,956 $ 39.70 5.2 years $ 40,310 We estimate that 815,069 of the non-vested stock options outstanding at September 30, 2016 will ultimately vest. The aggregate intrinsic value in the table above represents the total pre-tax difference between the $73.10 closing price of our ordinary shares on September 30, 2016 over the exercise prices of the stock options, multiplied by the number of options outstanding or outstanding and exercisable, as applicable. The aggregate intrinsic value is not recorded for financial accounting purposes and the value changes daily based on the daily changes in the fair market value of ordinary shares. The total intrinsic value of stock options exercised during the first half of fiscal 2017 and fiscal 2016 was $3,386 and $8,295 , respectively. Net cash proceeds from the exercise of stock options were $2,494 and $8,111 for the first half of fiscal 2017 and fiscal 2016 , respectively. The weighted average grant date fair value of stock option grants was $13.42 and $14.66 for the first half of fiscal 2017 and fiscal 2016 , respectively. Stock appreciation rights (“SARS”) carry generally the same terms and vesting requirements as stock options except that they are settled in cash upon exercise and therefore, are classified as liabilities. The fair value of the outstanding SARS as of September 30, 2016 and 2015 was $2,001 and $1,954 , respectively. A summary of the non-vested restricted share activity is presented below: Number of Restricted Shares Number of Restricted Share Units Weighted-Average Grant Date Fair Value Non-vested at March 31, 2016 872,972 41,641 $ 51.98 Granted 226,027 19,634 69.86 Vested (207,629 ) (20,424 ) 40.49 Canceled (26,603 ) (2,275 ) 61.71 Non-vested at September 30, 2016 864,767 38,576 $ 59.43 Restricted shares granted are valued based on the closing stock price at the grant date. The value of restricted shares that vested during the first half of fiscal 2017 was $7,971 . Restricted share units carry generally the same terms and vesting requirements as restricted stock except that they may be settled in stock or cash upon vesting. Those that are settled in cash are classified as liabilities. All outstanding cash-settled restricted share units vested during fiscal year 2016. The fair value of cash-settled restricted share units are revalued at each reporting date and the related liability and expense are adjusted accordingly. The tax benefit from share-based compensation was $3,454 and $4,676 for the first half of fiscal 2017 and fiscal 2016 , respectively. As of September 30, 2016 , there was a total of $42,715 in unrecognized compensation cost related to non-vested share-based compensation granted under our share-based compensation plans. We expect to recognize the cost over a weighted average period of 2.30 years.

Financial and Other Guarantees

Financial and Other Guarantees	6 Months Ended
	Sep. 30, 2016
Notes To Financial Statements [Abstract]
Product Warranty Disclosure [Text Block]	Financial and Other Guarantees We generally offer a limited parts and labor warranty on capital equipment. The specific terms and conditions of those warranties vary depending on the product sold and the countries where we conduct business. We record a liability for the estimated cost of product warranties at the time product revenues are recognized. The amounts we expect to incur on behalf of our Customers for the future estimated cost of these warranties are recorded as a current liability on the accompanying Consolidated Balance Sheets. Factors that affect the amount of our warranty liability include the number and type of installed units, historical and anticipated rates of product failures, and material and service costs per claim. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary. Changes in our warranty liability during the first half of fiscal 2017 were as follows: Balance, March 31, 2016 $ 5,909 Warranties issued during the period 5,897 Settlements made during the period (5,340 ) Balance, September 30, 2016 $ 6,466 We also sell product maintenance contracts to our Customers. These contracts range in terms from one to five years and require us to maintain and repair the product over the maintenance contract term. We initially record amounts due from Customers under these contracts as a liability for deferred service contract revenue on the accompanying Consolidated Balance Sheets within “Accrued expenses and other.” The liability recorded for such deferred service revenue was $37,213 and $33,416 as of September 30, 2016 and March 31, 2016 , respectively. Such deferred revenue is then amortized on a straight-line basis over the contract term and recognized as service revenue on our accompanying Consolidated Statements of Income. The activity related to the liability for deferred service contract revenue is excluded from the table presented above.

Forward and Swap Contracts

Forward and Swap Contracts	6 Months Ended
	Sep. 30, 2016
Notes To Financial Statements [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	Derivatives and Hedging From time to time, we enter into forward contracts to hedge potential foreign currency gains and losses that arise from transactions denominated in foreign currencies, including inter-company transactions. We may also enter into commodity swap contracts to hedge price changes in nickel that impact raw materials included in our cost of revenues. We do not use derivative financial instruments for speculative purposes. These contracts are not designated as hedging instruments and do not receive hedge accounting treatment; therefore, changes in their fair value are not deferred but are recognized immediately in the Consolidated Statements of Income. At September 30, 2016 , we held foreign currency forward contracts to buy 65.0 million Mexican pesos, 7.0 million British pounds sterling, 3.0 million euros, and 10.0 million Canadian dollars. At September 30, 2016 we held commodity swap contracts to buy 349.3 thousand pounds of nickel. Asset Derivatives Liability Derivatives Balance Sheet Fair Value at Fair Value at Fair Value at Fair Value at Location September 30, 2016 March 31, 2016 September 30, 2016 March 31, 2016 Prepaid & Other $ 405 $ 145 $ — $ — Accrued expenses and other $ — $ — $ 24 $ 122 The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income: Location of gain (loss) recognized in income Amount of gain (loss) recognized in income Three Months Ended September 30, Six Months Ended September 30, 2016 2015 2016 2015 Foreign currency forward contracts Selling, general and administrative $ (531 ) $ (693 ) $ (1,550 ) $ (261 ) Commodity swap contracts Cost of revenues $ 205 $ (288 ) $ 416 $ (333 ) Additionally, we hold our debt in multiple currencies to fund our operations and investments in certain subsidiaries. We designate portions of foreign currency denominated intercompany loans as hedges of portions of net investments in foreign operations. Net debt designated as non-derivative net investment hedging instruments totaled $122,200 at September 30, 2016. These hedges are designed to be fully effective and any associated gain or loss is recognized in Accumulated Other Comprehensive Income and will be reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Sep. 30, 2016
Notes To Financial Statements [Abstract]
Fair Value, Measurement Inputs, Disclosure [Text Block]	Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. We estimate the fair value of financial assets and liabilities using available market information and generally accepted valuation methodologies. The inputs used to measure fair value are classified into three tiers. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the entity to develop its own assumptions. The following table shows the fair value of our financial assets and liabilities at September 30, 2016 and March 31, 2016: Fair Value Measurements at September 30, 2016 and March 31, 2016 Using Carrying Value Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Level 1 Level 2 Level 3 September 30 March 31 September 30 March 31 September 30 March 31 September 30 March 31 Assets: Cash and cash equivalents (1) $ 254,351 $ 248,841 $ 254,351 $ 225,090 $ — $ 23,751 $ — $ — Forward and swap contracts (2) 405 145 — — 405 145 — — Investments (3) 11,768 6,192 11,768 6,192 — — — — Liabilities: Forward and swap contracts (2) $ 24 $ 122 $ — $ — $ 24 $ 122 $ — $ — Deferred compensation plans (3) 1,735 1,765 1,735 1,765 — — — — Long term debt (4) 1,504,192 1,567,796 — — 1,548,656 1,592,184 — — Contingent consideration obligations (5) 7,420 5,886 — — — — 7,420 5,886 (1) Money market fund holdings are classified as level two as active market quoted prices are not available. (2) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. (3) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Changes in the value of the investment accounts are recognized each period based on the fair value of the underlying investments. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers including an incremental investment of $4,564 made in April 2016. (4) We estimate the fair value of our principal amount of long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements. (5) Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates. The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at September 30, 2016 are summarized as follows: Contingent Consideration Balance at March 31, 2016 $ 5,886 Additions 2,348 Payments (182 ) Foreign currency translation adjustments (1) (632 ) Balance at September 30, 2016 $ 7,420 (1) Reported in other comprehensive income (loss) . Information regarding our investments is as follows: Investments at September 30, 2016 and March 31, 2016 Cost Unrealized Gains Unrealized Losses (2) Fair Value September 30 March 31 September 30 March 31 September 30 March 31 September 30 March 31 Available-for-sale securities: Marketable equity securities (1) $ 11,037 $ 4,681 $ — $ — $ (918 ) $ (185 ) $ 10,119 $ 4,496 Mutual funds 1,187 1,289 462 407 — — 1,649 1,696 Total available-for-sale securities $ 12,224 $ 5,970 $ 462 $ 407 $ (918 ) $ (185 ) $ 11,768 $ 6,192 (1) Our marketable equity securities have been in a unrealized loss position for less than 12 months. (2) Amounts reported include the impact of foreign currency movements relative to the U.S. dollar.

Reclassifications out of Accumu

Reclassifications out of Accumulated Other Comprehensive Income (Notes)	6 Months Ended
	Sep. 30, 2016
Reclassifications out of AOCI [Abstract]
Comprehensive Income (Loss) Note [Text Block]	Reclassifications Out of Accumulated Other Comprehensive Income (Loss) Amounts in Accumulated Other Comprehensive Income (Loss) are presented net of the related tax. Foreign Currency Translation is not adjusted for income taxes. Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three and six months ended September 30, 2016 were as follows: Gain (Loss) on Available for Sale Securities (1) Defined Benefit Plans (2) Foreign Currency Translation (3) Total Accumulated Other Comprehensive Income Three Months Six Months Three Months Six Months Three Months Six Months Three Months Six Months Beginning Balance $ (793 ) $ (673 ) $ 4,718 $ 5,108 $ (89,643 ) $ (72,594 ) $ (85,718 ) $ (68,159 ) Other Comprehensive Income (Loss) before reclassifications 17 (131 ) 103 206 (7,946 ) (24,995 ) (7,826 ) (24,920 ) Amounts reclassified from Accumulated Other Comprehensive Income (Loss) 9 37 (493 ) (986 ) — — (484 ) (949 ) Net current-period Other Comprehensive Income (Loss) 26 (94 ) (390 ) (780 ) (7,946 ) (24,995 ) (8,310 ) (25,869 ) Balance at September 30, 2016 $ (767 ) $ (767 ) $ 4,328 $ 4,328 $ (97,589 ) $ (97,589 ) $ (94,028 ) $ (94,028 ) Details of amounts reclassified from Accumulated Other Comprehensive Income (Loss) are as follows: (1) Realized gain (loss) on available for sale securities is reported in the interest income and miscellaneous expense line of the Consolidated Statements of Income. (2) Amortization (gain) of defined benefit pension items is reported in the selling, general and administrative expense line of the Consolidated Statements of Income. (3) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.

Nature of Operations and Summ24

Nature of Operations and Summary of Significant Accounting Policies Accounting Policies (Policies)	6 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation
Use of Estimates, Policy [Policy Text Block]	Use of Estimates We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three and six month periods ended September 30, 2016 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2017 .
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Standards Impacting the Company Recently issued accounting standards impacting the Company are presented in the following table: Standard Date of Issuance Description Date of Adoption Effect on the financial statements or other significant matters Standards that have recently been adopted ASU 2015-05, "Goodwill and other-Internal-Use Software" (Subtopic 350-40) April 2015 The standard provides guidance on a customer's accounting for fees paid in cloud computing arrangements. Previously, there was no U.S. GAAP guidance on accounting for such fees from the customer's perspective. Under the standard, customers will apply the same criteria as vendors to determine whether the arrangement contains a software license or is solely a service contract. The determination could impact the classification of advance payments in the statements of financial position and cash flows as well as the classification of the expenses in the results of operations. The standard is effective for annual periods beginning after December 15, 2015 and interim periods within that period. Early adoption is permitted. First Quarter Fiscal 2017 The adoption of this standard did not have a material impact on our statements of consolidated financial position, results of operations and cash flows. ASU 2016-09, "Stock Compensation: Improvements to Employee Share-Based Payment Accounting" (Topic 718) March 2016 The update simplifies several aspects of the accounting for share-based payment award transactions, including income tax consequences, the classification of awards as either equity or liabilities, and the classification on the statement of cash flows. The standard is effective for annual periods beginning after December 15, 2016 and interim periods within that period. Early adoption is permitted. First Quarter Fiscal 2017 As a result of the adoption of this standard, we recorded $3.5 million of excess tax benefits associated with share based compensation in the statement of income for the six months ended September 30, 2016 and have included the associated cash flows as cash provided by operating activities. Prior periods have not been restated. Standards that have yet to be adopted ASU 2014-09, "Revenue from Contracts with Customers" May 2014 The standard will replace existing revenue recognition standards and significantly expand the disclosure requirements for revenue arrangements. It may be adopted either retrospectively or on a modified retrospective basis to new contracts and existing contracts with remaining performance obligations as of the effective date. The standard update is effective for annual periods beginning after December 15, 2017 and interim periods within that period, early adoption is not permitted before the original public entity effective date of December 15, 2016. N/A We are currently in the process of evaluating the impact that the standard will have on our consolidated financial position, results of operations and cash flows. ASU 2016-02, "Leases" (Topic 842) February 2016 The update will require lessees to record all leases, whether finance or operating, on the balance sheet. An asset will be recorded to represent the right to use the leased asset, and a liability will be recorded to represent the lease obligation. The standard is effective for annual periods beginning after December 15, 2018 and interim periods within that period. Early adoption is permitted. N/A We are in the process of evaluating the impact that the standard will have on our statements of consolidated financial position, results of operations and cash flows. ASU 2016-07, "Investments - Equity Method and Joint Ventures, Simplifying the Transition to the Equity Method of Accounting" (Topic 323) March 2016 The update replaces the previous requirement to retroactively adopt the equity method. The new standard requires that the equity method investor add the cost of acquiring the additional interest in the investee to the current basis of the investor's previously held interest and adopt the equity method of accounting as of the date the investment becomes qualified for equity method accounting. The standard is effective for annual periods beginning after December 15, 2016 and interim periods within that period. Early adoption is permitted. N/A We do not expect the adoption of this standard to have a material impact on our statements of consolidated financial position, results of operations and cash flows. ASU 2016-15, "Statement of Cash Flows" (Topic 230) August 2016 This update provides guidance on the following several specific cash flow issues: Debt prepayment or debt extinguishment costs, Settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies, distributions received from equity method investees, beneficial interests in securitization transactions, and separately identifiable cash flows and application of the predominance principle. The standard is effective for annual periods beginning after December 15, 2017 and interim periods within that period. Early adoption is permitted. N/A We are in the process of evaluating the impact that the standard will have on our statement of cash flows.

Business Acquisitions and Div25

Business Acquisitions and Divestitures (Tables)	6 Months Ended
	Sep. 30, 2016
Business Acquisitions and Divestitures [Abstract]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	The Consolidated Financial Statements include the operating results of acquisitions from the acquisition dates. The table below summarizes the preliminary allocation of the purchase price to the net assets acquired based on fair values at the acquisition date. Fiscal Year 2017 (1) Fiscal Year 2016 (1) Medisafe Compass Phoenix and Endo-Tek Synergy Cash $ 3,767 $ — $ 769 $ 53,057 Accounts receivable 3,703 262 1,123 107,341 Inventory 2,500 834 950 30,074 Property, plant and equipment 642 283 1,092 534,879 Other assets — 445 46 19,708 Intangible assets 12,239 5,826 — 806,526 Goodwill 20,706 8,739 12,794 1,411,781 Total Assets 43,557 16,389 16,774 2,963,366 Current liabilities (5,281 ) (387 ) (1,373 ) (108,192 ) Long-term indebtedness — — — (321,082 ) Non-current liabilities (227 ) — (295 ) (230,544 ) Total Liabilities (5,508 ) (387 ) (1,668 ) (659,818 ) Net Assets $ 38,049 $ 16,002 $ 15,106 $ 2,303,548 (1) Purchase price allocation are still preliminary as of September 30, 2016, as valuations have not been finalized.

Property, Plant and Equipment L

Property, Plant and Equipment Level 3 (Tables)	6 Months Ended
	Sep. 30, 2016
Notes To Financial Statements [Abstract]
Property, Plant and Equipment [Table Text Block]	Information related to the major categories of our depreciable assets is as follows: September 30, March 31, Land and land improvements (1) $ 38,995 $ 39,051 Buildings and leasehold improvements 445,124 446,277 Machinery and equipment 550,003 580,962 Linens 30,234 42,354 Information systems 132,140 126,180 Radioisotope 441,582 434,152 Construction in progress (1) 100,158 79,291 Total property, plant, and equipment 1,738,236 1,748,267 Less: accumulated depreciation and depletion (698,453 ) (683,948 ) Property, plant, and equipment, net $ 1,039,783 $ 1,064,319 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service.

Inventories, Net Level 3 (Table

Inventories, Net Level 3 (Tables)	6 Months Ended
	Sep. 30, 2016
Notes To Financial Statements [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory costs include material, labor, and overhead. Inventories, net consisted of the following: September 30, March 31, Raw materials $ 68,476 $ 62,673 Work in process 23,481 19,614 Finished goods 153,902 146,820 LIFO reserve (17,299 ) (17,608 ) Reserve for excess and obsolete inventory (18,625 ) (18,707 ) Inventories, net $ 209,935 $ 192,792

Debt Level 3 (Tables)

Debt Level 3 (Tables)	6 Months Ended
	Sep. 30, 2016
Notes To Financial Statements [Abstract]
Schedule of Debt [Table Text Block]	Indebtedness was as follows: September 30, March 31, Private Placement $ 666,000 $ 666,000 Deferred financing costs (3,178 ) (3,420 ) Credit Agreement 841,370 905,216 Total long term debt $ 1,504,192 $ 1,567,796

Additional Consolidated Balan29

Additional Consolidated Balance Sheets Information Level 3 (Tables)	6 Months Ended
	Sep. 30, 2016
Notes To Financial Statements [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Additional information related to our Consolidated Balance Sheets is as follows: September 30, March 31, Accrued payroll and other related liabilities: Compensation and related items $ 34,801 $ 30,175 Accrued vacation/paid time off 11,193 14,368 Accrued bonuses 12,892 31,502 Accrued employee commissions 11,826 13,809 Other postretirement benefit obligations-current portion 2,463 2,463 Other employee benefit plans obligations-current portion 849 1,659 Total accrued payroll and other related liabilities $ 74,024 $ 93,976 Accrued expenses and other: Deferred revenues $ 66,792 $ 56,238 Self-insured risk reserves-current portion 9,120 8,266 Accrued dealer commissions 14,070 12,717 Accrued warranty 6,466 5,909 Other 67,246 70,245 Total accrued expenses and other $ 163,694 $ 153,375 Other liabilities: Self-insured risk reserves-long-term portion $ 13,257 $ 13,257 Other postretirement benefit obligations-long-term portion 15,103 15,932 Defined benefit pension plans obligations-long-term portion 21,927 25,301 Other employee benefit plans obligations-long-term portion 4,063 4,366 Accrued long-term income taxes 3,779 — Asset retirement obligation-long-term portion 10,033 10,342 Other 10,649 15,100 Total other liabilities $ 78,811 $ 84,298

Benefit Plans Level 3 (Tables)

Benefit Plans Level 3 (Tables)	6 Months Ended
	Sep. 30, 2016
Notes To Financial Statements [Abstract]
Schedule of Defined Benefit Plans Disclosures [Table Text Block]	AMSCO Plan Other Defined Benefit Pension Plan Other Postretirement Benefits Plan Six Months Ended September 30, 2016 2015 2016 2015 2016 2015 Service cost $ — $ 27 $ 944 $ — $ — $ — Interest cost — 560 378 — 277 296 Expected return on plan assets — (1,008 ) — — — — Amortization of loss — 602 — — 369 414 Settlement — 26,470 — — — — Amortization of prior service cost — — — — (1,631 ) (1,631 ) Net periodic benefit cost $ — $ 26,651 $ 1,322 $ — $ (985 ) $ (921 )

Business Segment Information Le

Business Segment Information Level 3 (Tables)	6 Months Ended
	Sep. 30, 2016
Notes To Financial Statements [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Financial information for each of our segments is presented in the following tables: Three Months Ended September 30, Six Months Ended September 30, 2016 2015 2016 2015 Revenues: Healthcare Products $ 304,797 $ 291,724 $ 586,095 $ 552,809 Healthcare Specialty Services 142,775 70,565 300,663 138,807 Life Sciences 81,485 71,040 162,674 127,812 Applied Sterilization Technologies 115,601 55,839 232,174 109,528 Corporate and other 1,757 729 3,187 843 Total revenues $ 646,415 $ 489,897 $ 1,284,793 $ 929,799 Segment operating income: Healthcare Products $ 50,098 $ 40,414 $ 84,737 $ 69,764 Healthcare Specialty Services 2,175 5,092 5,493 8,992 Life Sciences 22,772 20,883 47,234 34,333 Applied Sterilization Technologies 40,761 17,493 80,364 34,036 Corporate and other (4,741 ) (4,034 ) (5,237 ) (5,932 ) Total segment operating income $ 111,065 $ 79,848 $ 212,591 $ 141,193 Less: Adjustments Restructuring charges (1) $ 48 $ (15 ) $ 202 $ (464 ) Amortization of acquired intangible assets (2) 17,779 6,682 37,308 12,703 Acquisition and integration related charges (3) 6,638 23,982 11,873 35,528 Loss on fair value adjustment of acquisition related contingent consideration 1,850 — 1,850 — Net loss on divestiture of businesses (2) 13,802 — 13,802 — Amortization of inventory and property "step up" to fair value (2) 1,385 21 4,471 32 Settlement of pension obligation (4) — 26,515 — 26,515 Total operating income $ 69,563 $ 22,663 $ 143,085 $ 66,879

Shares and Preferred Shares Lev

Shares and Preferred Shares Level 3 (Tables)	6 Months Ended
	Sep. 30, 2016
Notes To Financial Statements [Abstract]
Schedule of Weighted Average Number of Shares [Table Text Block]	The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share: Three Months Ended September 30, Six Months Ended September 30, 2016 2015 2016 2015 Denominator (shares in thousands): Weighted average shares outstanding—basic 85,851 59,897 85,944 59,832 Dilutive effect of share equivalents 482 473 482 496 Weighted average shares outstanding and share equivalents—diluted 86,333 60,370 86,426 60,328
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive: Three Months Ended September 30, Six Months Ended September 30, 2016 2015 2016 2015 (shares in thousands) Number of share options 627 419 496 235

Share-Based Compensation Level

Share-Based Compensation Level 3 (Tables)	6 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Assumptions Used	The following weighted-average assumptions were used for options granted during the first half of fiscal 2017 and 2016 : Fiscal 2017 Fiscal 2016 Risk-free interest rate 1.29 % 1.51 % Expected life of options 5.66 years 5.69 years Expected dividend yield of stock 1.54 % 1.40 % Expected volatility of stock 22.92 % 25.06 %
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding	A summary of share option activity is as follows: Number of Options Weighted Average Exercise Price Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at March 31, 2016 1,729,517 $ 44.01 Granted 402,141 69.85 Exercised (81,539 ) 29.44 Forfeited (9,226 ) 64.43 Canceled (470 ) 25.98 Outstanding at September 30, 2016 2,040,423 $ 49.59 6.7 years $ 47,968 Exercisable at September 30, 2016 1,206,956 $ 39.70 5.2 years $ 40,310
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	A summary of the non-vested restricted share activity is presented below: Number of Restricted Shares Number of Restricted Share Units Weighted-Average Grant Date Fair Value Non-vested at March 31, 2016 872,972 41,641 $ 51.98 Granted 226,027 19,634 69.86 Vested (207,629 ) (20,424 ) 40.49 Canceled (26,603 ) (2,275 ) 61.71 Non-vested at September 30, 2016 864,767 38,576 $ 59.43

Financial and Other Guarantees

Financial and Other Guarantees Level 3 (Tables)	6 Months Ended
	Sep. 30, 2016
Notes To Financial Statements [Abstract]
Schedule of Guarantor Obligations [Table Text Block]	Changes in our warranty liability during the first half of fiscal 2017 were as follows: Balance, March 31, 2016 $ 5,909 Warranties issued during the period 5,897 Settlements made during the period (5,340 ) Balance, September 30, 2016 $ 6,466

Derivatives and Hedging Level 3

Derivatives and Hedging Level 3 (Tables)	6 Months Ended
	Sep. 30, 2016
Notes To Financial Statements [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	Asset Derivatives Liability Derivatives Balance Sheet Fair Value at Fair Value at Fair Value at Fair Value at Location September 30, 2016 March 31, 2016 September 30, 2016 March 31, 2016 Prepaid & Other $ 405 $ 145 $ — $ — Accrued expenses and other $ — $ — $ 24 $ 122
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income: Location of gain (loss) recognized in income Amount of gain (loss) recognized in income Three Months Ended September 30, Six Months Ended September 30, 2016 2015 2016 2015 Foreign currency forward contracts Selling, general and administrative $ (531 ) $ (693 ) $ (1,550 ) $ (261 ) Commodity swap contracts Cost of revenues $ 205 $ (288 ) $ 416 $ (333 )

Fair Value Measurements Level 3

Fair Value Measurements Level 3 (Tables)	6 Months Ended
	Sep. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The following table shows the fair value of our financial assets and liabilities at September 30, 2016 and March 31, 2016: Fair Value Measurements at September 30, 2016 and March 31, 2016 Using Carrying Value Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Level 1 Level 2 Level 3 September 30 March 31 September 30 March 31 September 30 March 31 September 30 March 31 Assets: Cash and cash equivalents (1) $ 254,351 $ 248,841 $ 254,351 $ 225,090 $ — $ 23,751 $ — $ — Forward and swap contracts (2) 405 145 — — 405 145 — — Investments (3) 11,768 6,192 11,768 6,192 — — — — Liabilities: Forward and swap contracts (2) $ 24 $ 122 $ — $ — $ 24 $ 122 $ — $ — Deferred compensation plans (3) 1,735 1,765 1,735 1,765 — — — — Long term debt (4) 1,504,192 1,567,796 — — 1,548,656 1,592,184 — — Contingent consideration obligations (5) 7,420 5,886 — — — — 7,420 5,886 (1) Money market fund holdings are classified as level two as active market quoted prices are not available. (2) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. (3) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Changes in the value of the investment accounts are recognized each period based on the fair value of the underlying investments. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers including an incremental investment of $4,564 made in April 2016. (4) We estimate the fair value of our principal amount of long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements. (5) Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.
Schedule of Level 3 Contingent Consideration [Table Text Block]	The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at September 30, 2016 are summarized as follows: Contingent Consideration Balance at March 31, 2016 $ 5,886 Additions 2,348 Payments (182 ) Foreign currency translation adjustments (1) (632 ) Balance at September 30, 2016 $ 7,420 (1) Reported in other comprehensive income (loss) . Information regarding our investments is as follows: Investments at September 30, 2016 and March 31, 2016 Cost Unrealized Gains Unrealized Losses (2) Fair Value September 30 March 31 September 30 March 31 September 30 March 31 September 30 March 31 Available-for-sale securities: Marketable equity securities (1) $ 11,037 $ 4,681 $ — $ — $ (918 ) $ (185 ) $ 10,119 $ 4,496 Mutual funds 1,187 1,289 462 407 — — 1,649 1,696 Total available-for-sale securities $ 12,224 $ 5,970 $ 462 $ 407 $ (918 ) $ (185 ) $ 11,768 $ 6,192 (1) Our marketable equity securities have been in a unrealized loss position for less than 12 months. (2) Amounts reported include the impact of foreign currency movements relative to the U.S. dollar.
Unrealized Gain (Loss) on Investments [Table Text Block]	Information regarding our investments is as follows: Investments at September 30, 2016 and March 31, 2016 Cost Unrealized Gains Unrealized Losses (2) Fair Value September 30 March 31 September 30 March 31 September 30 March 31 September 30 March 31 Available-for-sale securities: Marketable equity securities (1) $ 11,037 $ 4,681 $ — $ — $ (918 ) $ (185 ) $ 10,119 $ 4,496 Mutual funds 1,187 1,289 462 407 — — 1,649 1,696 Total available-for-sale securities $ 12,224 $ 5,970 $ 462 $ 407 $ (918 ) $ (185 ) $ 11,768 $ 6,192

Reclassifications out of Accu37

Reclassifications out of Accumulated Other Comprehensive Income (Tables)	6 Months Ended
	Sep. 30, 2016
Reclassifications out of AOCI [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three and six months ended September 30, 2016 were as follows: Gain (Loss) on Available for Sale Securities (1) Defined Benefit Plans (2) Foreign Currency Translation (3) Total Accumulated Other Comprehensive Income Three Months Six Months Three Months Six Months Three Months Six Months Three Months Six Months Beginning Balance $ (793 ) $ (673 ) $ 4,718 $ 5,108 $ (89,643 ) $ (72,594 ) $ (85,718 ) $ (68,159 ) Other Comprehensive Income (Loss) before reclassifications 17 (131 ) 103 206 (7,946 ) (24,995 ) (7,826 ) (24,920 ) Amounts reclassified from Accumulated Other Comprehensive Income (Loss) 9 37 (493 ) (986 ) — — (484 ) (949 ) Net current-period Other Comprehensive Income (Loss) 26 (94 ) (390 ) (780 ) (7,946 ) (24,995 ) (8,310 ) (25,869 ) Balance at September 30, 2016 $ (767 ) $ (767 ) $ 4,328 $ 4,328 $ (97,589 ) $ (97,589 ) $ (94,028 ) $ (94,028 ) Details of amounts reclassified from Accumulated Other Comprehensive Income (Loss) are as follows: (1) Realized gain (loss) on available for sale securities is reported in the interest income and miscellaneous expense line of the Consolidated Statements of Income. (2) Amortization (gain) of defined benefit pension items is reported in the selling, general and administrative expense line of the Consolidated Statements of Income. (3) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.

Nature of Operations and Summ38

Nature of Operations and Summary of Significant Accounting Policies Level 4 (Details)	6 Months Ended
	Sep. 30, 2016USD ($)
Loss Contingencies [Line Items]
Proceeds and Excess Tax Benefit from Share-based Compensation	$ 3,500,000

Business Acquisitions and Div39

Business Acquisitions and Divestitures (Details)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Mar. 31, 2016USD ($)	Sep. 16, 2016USD ($)	Aug. 31, 2016USD ($)	Jul. 22, 2016USD ($)	Nov. 02, 2015£ / shares	Nov. 02, 2015USD ($)$ / shares
Business Acquisition [Line Items]
Revenues	$ 646,415,000	$ 489,897,000	$ 1,284,793,000	$ 929,799,000
Proceeds from Divestiture of Businesses			131,586,000	0
STERIS Closing Stock Price at 11/02/2015 | $ / shares										$ 73.02
Gain (Loss) on Disposition of Business	(13,802,000)	$ 0	(13,802,000)	$ 0
Compass Medical [Member]
Business Acquisition [Line Items]
Purchase price of acquired entity						$ 16,000,000
Revenues					$ 6,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents	0		0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables	262,000		262,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	834,000		834,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	283,000		283,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other	445,000		445,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	5,826,000		5,826,000
Goodwill	8,739,000		8,739,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets	16,389,000		16,389,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities	(387,000)		(387,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	0		0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities	0		0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	(387,000)		(387,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	16,002,000		16,002,000
Phoenix and Endo-Tek [Member]
Business Acquisition [Line Items]
Purchase price of acquired entity							$ 14,300,000
Revenues					8,000,000
Business Acquisition, Percentage of Voting Interests Acquired							100.00%
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents	769,000		769,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables	1,123,000		1,123,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	950,000		950,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	1,092,000		1,092,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other	46,000		46,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	0		0
Goodwill	12,794,000		12,794,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets	16,774,000		16,774,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities	(1,373,000)		(1,373,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	0		0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities	(295,000)		(295,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	(1,668,000)		(1,668,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	15,106,000		15,106,000
Medisafe [Member]
Business Acquisition [Line Items]
Purchase price of acquired entity								$ 34,300,000
Revenues					$ 18,000,000
Business Acquisition, Percentage of Voting Interests Acquired								100.00%
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents	3,767,000		3,767,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables	3,703,000		3,703,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	2,500,000		2,500,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	642,000		642,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other	0		0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	12,239,000		12,239,000
Goodwill	20,706,000		20,706,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets	43,557,000		43,557,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities	(5,281,000)		(5,281,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	0		0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities	(227,000)		(227,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	(5,508,000)		(5,508,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	38,049,000		$ 38,049,000
Synergy Health plc [Member]
Business Acquisition [Line Items]
Approximate purchase price of entity										$ 2,300,000,000
Number of Countries in which Entity Operates					100
Entity Number of Employees					14,000
Business Acquisition, Transaction Costs					$ 63,789,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents					53,057,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables					107,341,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory					30,074,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment					534,879,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other					19,708,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill					806,526,000
Goodwill					1,411,781,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets					2,963,366,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities					(108,192,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt					(321,082,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities					(230,544,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities					(659,818,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net					2,303,548,000
Applied Infection Control [Member]
Business Acquisition [Line Items]
Revenues					50,000,000
Proceeds from Divestiture of Businesses	41,800,000
Gain (Loss) on Disposition of Business	35,000,000
UK Linen Management Services [Member]
Business Acquisition [Line Items]
Revenues					50,000,000
Proceeds from Divestiture of Businesses	65,000,000
Gain (Loss) on Disposition of Business	65,400,000
Synergy Health Labs [Member]
Business Acquisition [Line Items]
Revenues					$ 15,000,000
Proceeds from Divestiture of Businesses	24,900,000
Gain (Loss) on Disposition of Business	$ 16,500,000
United States of America, Dollars
Business Acquisition [Line Items]
Value of transaction per Synergy Share | $ / shares										$ 38.17
United Kingdom, Pounds
Business Acquisition [Line Items]
Value of transaction per Synergy Share | £ / shares									£ 24.80

Property, Plant and Equipment40

Property, Plant and Equipment Level 4 (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Mar. 31, 2016
Property, Plant and Equipment [Line Items]
Land	$ 38,995	$ 39,051
Buildings and Improvements, Gross	445,124	446,277
Machinery and Equipment, Gross	550,003	580,962
Linen	30,234	42,354
Capitalized Computer Software, Gross	132,140	126,180
Materials, Supplies, and Other	441,582	434,152
Construction in Progress, Gross	100,158	79,291
Property, Plant and Equipment, Gross	1,738,236	1,748,267
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(698,453)	(683,948)
Property, Plant and Equipment, Net	$ 1,039,783	$ 1,064,319

Inventories, Net Level 4 (Detai

Inventories, Net Level 4 (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Mar. 31, 2016
Inventory, Raw Materials	$ 68,476	$ 62,673
Inventory, Work in Process	23,481	19,614
Inventory, Finished Goods	153,902	146,820
Inventory, LIFO Reserve	(17,299)	(17,608)
Inventory Valuation Reserves	(18,625)	(18,707)
Inventory, Net	$ 209,935	$ 192,792

Debt Level 4 (Details)

Debt Level 4 (Details) - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016
Debt Instrument [Line Items]
Proceeds from Issuance of Private Placement	$ 0	$ 350,000
Debt Instrument, Face Amount	666,000		$ 666,000
Deferred Finance Costs, Own-share Lending Arrangement, Issuance Costs, Net	(3,178)		(3,420)
Line of Credit Facility, Amount Outstanding	841,370		905,216
Long-term Debt	$ 1,504,192		$ 1,567,796

Additional Consolidated Balan43

Additional Consolidated Balance Sheets Information Level 4 (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Mar. 31, 2016
Employee-related Liabilities	$ 34,801	$ 30,175
Accrued Vacation	11,193	14,368
Accrued Bonuses	12,892	31,502
Accrued Liabilities for Commissions, Expense and Taxes	11,826	13,809
Other Postretirement Benefits Payable	2,463	2,463
Pension and Other Postretirement and Postemployment Benefit Plans, Liabilities	849	1,659
Employee-related Liabilities, Current	74,024	93,976
Deferred Revenue	66,792	56,238
Self Insurance Reserve, Current	9,120	8,266
Accrued Sales Commission	14,070	12,717
Product Warranty Accrual	6,466	5,909
Other Accrued Liabilities	67,246	70,245
Accrued Liabilities	163,694	153,375
Self Insurance Reserve, Noncurrent	13,257	13,257
Other Postretirement Benefits Payable, Noncurrent	15,103	15,932
Defined Benefit Pension Plan, Liabilities, Noncurrent	21,927	25,301
Pension and Other Postretirement and Postemployment Benefit Plans, Liabilities, Noncurrent	4,063	4,366
Accrued Income Taxes, Noncurrent	3,779	0
Asset Retirement Obligations, Noncurrent	10,033	10,342
Other Liabilities	10,649	15,100
Other Liabilities, Noncurrent	$ 78,811	$ 84,298

Income Tax Expense Unrecognized

Income Tax Expense Unrecognized Tax Benefits (Details)	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Effective Income Tax Rate, Continuing Operations	31.80%	46.40%	27.00%	39.70%

Benefit Plans Level 4 (Details)

Benefit Plans Level 4 (Details) - USD ($)	Aug. 26, 2015	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016	Aug. 19, 2015	Sep. 30, 2008
Defined Benefit Plan Disclosure [Line Items]
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 4,641,000
Defined Benefit Plan, Accumulated Benefit Obligation								$ 46,001,000
DBP Purchase Price of Annuity Contract							$ 51,805,000
Defined Benefit Plan, Settlements, Benefit Obligation		$ 0	$ 26,515,000	$ 0	$ 26,515,000	$ 26,470,000
United States Pension Plans of US Entity, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost		0	11,000	0	27,000
Defined Benefit Plan, Interest Cost		0	224,000	0	560,000
Defined Benefit Plan, Expected Return on Plan Assets		0	(403,000)	0	(1,008,000)
Defined Benefit Plan, Amortization of Gains (Losses)		0	241,000	0	602,000
Defined Benefit Plan, Recognized Net Gain (Loss) Due to Settlements and Curtailments		0	26,470,000	0	26,470,000
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)		0	0	0	0
Defined Benefit Plan, Net Periodic Benefit Cost		0	26,543,000	0	26,651,000
Other Defined Benefit Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost		472,000	0	944,000	0
Defined Benefit Plan, Interest Cost		189,000	0	378,000	0
Defined Benefit Plan, Expected Return on Plan Assets		0	0	0	0
Defined Benefit Plan, Amortization of Gains (Losses)		0	0	0	0
Defined Benefit Plan, Recognized Net Gain (Loss) Due to Settlements and Curtailments		0	0	0	0
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)		0	0	0	0
Defined Benefit Plan, Net Periodic Benefit Cost		661,000	0	1,322,000	0
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost		0	0	0	0
Defined Benefit Plan, Interest Cost		139,000	148,000	277,000	296,000
Defined Benefit Plan, Expected Return on Plan Assets		0	0	0	0
Defined Benefit Plan, Amortization of Gains (Losses)		184,000	207,000	369,000	414,000
Defined Benefit Plan, Recognized Net Gain (Loss) Due to Settlements and Curtailments		0	0	0	0
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)		(816,000)	(815,000)	(1,631,000)	(1,631,000)
Defined Benefit Plan, Net Periodic Benefit Cost		$ (493,000)	$ (460,000)	$ (985,000)	$ (921,000)

Business Segment Information 46

Business Segment Information Level 4 (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016
Segment Reporting Information [Line Items]
Assets	$ 5,210,625		$ 5,210,625		$ 5,346,416
Revenues	646,415	$ 489,897	1,284,793	$ 929,799
Operating Income (Loss)	69,563	22,663	143,085	66,879
Restructuring Charges	(48)	(15)	(202)	(464)
amortization and impairment of acquired intangible assets	17,779	6,682	37,308	12,703
acquisition and integration related charges	6,638	23,982	11,873	35,528
loss (gain) on fair value contingent consideration adjustments	1,850	0	1,850	0
Gain (Loss) on Disposition of Business	13,802	0	13,802	0
amortization of inventory and property step up to fair value	1,385	21	4,471	32
Defined Benefit Plan, Settlements, Benefit Obligation	0	26,515	0	26,515	$ 26,470
Healthcare Products [Member] [Member]
Segment Reporting Information [Line Items]
Revenues	304,797	291,724	586,095	552,809
Operating Income (Loss)	50,098	40,414	84,737	69,764
Healthcare Specialty Services [Member]
Segment Reporting Information [Line Items]
Revenues	142,775	70,565	300,663	138,807
Operating Income (Loss)	2,175	5,092	5,493	8,992
Life Science Member [Member]
Segment Reporting Information [Line Items]
Revenues	81,485	71,040	162,674	127,812
Operating Income (Loss)	22,772	20,883	47,234	34,333
Applied Sterilization Technologies [Member]
Segment Reporting Information [Line Items]
Revenues	115,601	55,839	232,174	109,528
Operating Income (Loss)	40,761	17,493	80,364	34,036
OperatingSegmentCorpandOther [Member]
Segment Reporting Information [Line Items]
Revenues	1,757	729	3,187	843
Operating Income (Loss)	(4,741)	(4,034)	(5,237)	(5,932)
OperatingSegmentAll [Member]
Segment Reporting Information [Line Items]
Revenues	646,415	489,897	1,284,793	929,799
Operating Income (Loss)	$ 111,065	$ 79,848	$ 212,591	$ 141,193

Shares and Preferred Shares L47

Shares and Preferred Shares Level 4 (Details) shares in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2016£ / sharesshares	Sep. 30, 2015shares	Sep. 30, 2016£ / sharesshares	Sep. 30, 2015shares	Mar. 31, 2016$ / shares	Oct. 23, 2015£ / shares
Weighted Average Common Shares Outstanding Basic and Diluted [Line Items]
Preferred Stock, Par or Stated Value Per Share | (per share)	£ 0.10		£ 0.10		$ 0.15
Weighted Average Number of Shares Outstanding, Basic	85,851	59,897	85,944	59,832
Weighted Average Number Diluted Shares Outstanding Adjustment	482	473	482	496
Weighted Average Number of Shares Outstanding, Diluted	86,333	60,370	86,426	60,328
United Kingdom, Pounds
Weighted Average Common Shares Outstanding Basic and Diluted [Line Items]
Preferred Stock, Par or Stated Value Per Share | £ / shares						£ 0.10

Shares and Preferred Shares Com

Shares and Preferred Shares Common share options (Details) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended		9 Months Ended
	Sep. 30, 2016£ / sharesshares	Sep. 30, 2015shares	Sep. 30, 2016£ / sharesshares	Sep. 30, 2015shares	Dec. 31, 2015	Sep. 30, 2016USD ($)shares	Mar. 31, 2016USD ($)$ / sharesshares	Oct. 23, 2015£ / shares	Oct. 23, 2015USD ($)$ / sharesshares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Preferred Stock, Shares Issued | shares						100,000	100,000		100,000
Preferred Stock, Par or Stated Value Per Share | (per share)	£ 0.10		£ 0.10				$ 0.15
Preferred Stock, Value, Issued | $						$ 15	$ 15
Preferred Stock, Dividend Rate, Percentage					5.00%
Preferred Stock, Redemption Price Per Share | (per share)								£ 0.10	$ 0.15
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares	627,000	419,000	496,000	235,000
United States of America, Dollars
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Preferred Stock, Par or Stated Value Per Share | $ / shares									$ 0.15
Preferred Stock, Value, Issued | $									$ 15

Repurchases of Shares Level 4 (

Repurchases of Shares Level 4 (Details) - USD ($) $ in Millions	6 Months Ended
	Sep. 30, 2016	Aug. 09, 2016
Schedule of Available-for-sale Securities [Line Items]
Stock Repurchase Program, Number of Shares Authorized to be Repurchased		$ 300
Stock Repurchased During Period, Shares	819,105
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	127,520

Share-Based Compensation Leve50

Share-Based Compensation Level 4 (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Nov. 08, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Item]
Remaining shares available for grant	5,588,018
Weighted-average assumptions used for options granted:
Risk-free interest rate	1.29%	1.51%
Expected life of options	5 years 7 months 28 days	5 years 8 months 8 days
Exptected dividend yield of stock	1.54%	1.40%
Expected volatility of stock	22.92%	25.06%
Estimated forfeiture rate	1.85%	1.55%
Summary of share option activity:
Number of Options, Outstanding, Beginning of Period	1,729,517
Weighted Average Exercise Price, Outstanding, Beginning of Period	$ 44.01
Number of Options, Granted	402,141
Weighted Average Exercise Price, Granted	$ 69.85
Number of Options, Exercised	(81,539)
Weighted Average Exercise Price, Exercised	$ 29.44
Number of Options, Forfeited	(9,226)
Weighted Average Exercise Price, Forfeited	$ 64.43
Number of Options, Canceled	(470)
Weighted Average Exercise Price, Canceled	$ 25.98
Number of Options, Outstanding, End of Period	2,040,423
Weighted Average Exercise Price, Outstanding, End of Period	$ 49.59
Average Remaining Contractual Term, Outstanding	6 years 8 months
Aggregate Intrinsic Value, Outstanding	$ 47,968
Number of Options, Exercisable	1,206,956
Weighted Average Exercise Price, Exercisable	$ 39.70
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	5 years 2 months
Aggregate Intrinsic Value, Exercisable	$ 40,310
Non-vested stock options outstanding expected to vest	815,069
Common Stock, Fair Market Value Per Share	$ 73.10
Total intrinsic value of stock options exercised	$ 3,386	$ 8,295
Net cash proceeds from the exercise of stock options	2,494	8,111
Tax benefit from stock option exercises	$ 3,454	$ 4,676
Weighted average grant date fair value of stock option grants, per share	$ 13.42	$ 14.66
Summary of non-vested restricted share activity:
Unrecognized compensation cost related to nonvested share-based compensation granted	$ 42,715
Weighted average period for recognition of unrecognized compensation cost	2 years 3 months 20 days
Stock Appreciation Rights (SARs) [Member]
Summary of non-vested restricted share activity:
FairValueOfOutstandingStockAppreciationRights	$ 2,001	$ 1,954
Restricted Stock
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	872,972
Weighted-Average Grant Date Fair Value, Non-vested at Beginning of Period	$ 51.98
Number of Restricted Shares, Granted	226,027
Weighted-Average Grant Date Fair Value, Granted	$ 69.86
Number of Restricted Shares, Vested	(207,629)
Weighted-Average Grant Date Fair Value, Vested	$ 40.49
Number of Restricted Shares, Canceled	(26,603)
Weighted-Average Grant Date Fair Value, Canceled	$ 61.71
Number of Restricted Shares, Non-vested at End of Period	864,767
Weighted-Average Grant Date Fair Value, Non-vested at End of Period	$ 59.43
Fair Value, Share-based Payment Awards, Other than Options	$ 7,971
Restricted Stock Units (RSUs)
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	41,641
Number of Restricted Shares, Granted	19,634
Number of Restricted Shares, Vested	(20,424)
Number of Restricted Shares, Canceled	(2,275)
Number of Restricted Shares, Non-vested at End of Period	38,576
Scenario, Forecast [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Item]
Remaining shares available for grant			4,031,196

Financial and Other Guarantee51

Financial and Other Guarantees Level 4 (Details) - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2016	Mar. 31, 2016
Guarantor Obligations [Line Items]
Deferred Service Revenue	$ 37,213	$ 33,416
Product Warranty Accrual	6,466	$ 5,909
Product Warranty Accrual, Warranties Issued	5,897
Standard Product Warranty Accrual, Payments	$ (5,340)

Derivatives and Hedging Level 4

Derivatives and Hedging Level 4 (Details) € in Thousands, MXN in Thousands, CAD in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016MXNlb	Sep. 30, 2016USD ($)lb	Sep. 30, 2016CADlb	Sep. 30, 2016EUR (€)lb	Mar. 31, 2016USD ($)
Derivative [Line Items]
Non-derivative Net Investment Hedge						$ 122,200
Other Assets [Member]
Derivative [Line Items]
Derivative Assets						405			$ 145
Derivative Liabilities						0			0
Accrued Liabilities [Member]
Derivative [Line Items]
Derivative Assets						0			0
Derivative Liabilities						$ 24			$ 122
Selling, General and Administrative Expenses [Member]
Derivative [Line Items]
Foreign Currency Transaction Loss, before Tax	$ (531)	$ (693)	$ (1,550)	$ (261)
Cost of Sales [Member]
Derivative [Line Items]
Gain (Loss) on Sale of Commodity Contracts	$ 205	$ (288)	$ 416	$ (333)
212234 Copper Ore and Nickel Ore Mining [Member]
Derivative [Line Items]
Investment Contract Weight | lb					349,300	349,300	349,300	349,300
Mexico, Pesos
Derivative [Line Items]
Derivative Liability, Notional Amount | MXN					MXN 65,000
Canada, Dollars
Derivative [Line Items]
Derivative Liability, Notional Amount | CAD							CAD 10,000
Euro Member Countries, Euro
Derivative [Line Items]
Derivative Liability, Notional Amount | €								€ 3,000

Fair Value Measurements Level 4

Fair Value Measurements Level 4 (Details) € in Thousands, £ in Thousands, MXN in Thousands		3 Months Ended			6 Months Ended
		Sep. 30, 2016USD ($)	Jun. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016MXN	Sep. 30, 2016GBP (£)	Sep. 30, 2016USD ($)		Sep. 30, 2016EUR (€)	Mar. 31, 2016USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Payments to Acquire Investments			$ 4,564,000		$ 6,356,000	$ 0
Available-for-sale Securities, Amortized Cost Basis									$ 12,224,000			$ 5,970,000
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax	[1]								462,000			407,000
Available-for-sale Equity Securities, Accumulated Gross Unrealized Loss, before Tax	[1]								(918,000)			(185,000)
Investments, Fair Value Disclosure									11,768,000			6,192,000
Business Combination, Contingent Consideration, Liability									7,420,000			5,886,000
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[2]								254,351,000			225,090,000
Foreign Currency Contract, Asset, Fair Value Disclosure	[3]								0			0
Foreign Currency Contracts, Liability, Fair Value Disclosure	[3]								0			0
Investments, Fair Value Disclosure	[4]								11,768,000			6,192,000
Deferred Compensation Plan Assets, Fair Value	[4]								1,735,000			1,765,000
Long-term Debt, Fair Value	[5]								0			0
Business Combination, Contingent Consideration, Liability									0	[6]		0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[2]								0			23,751,000
Foreign Currency Contract, Asset, Fair Value Disclosure	[3]								405,000			145,000
Foreign Currency Contracts, Liability, Fair Value Disclosure	[3]								24,000			122,000
Investments, Fair Value Disclosure									0	[4]		0
Deferred Compensation Plan Assets, Fair Value									0	[4]		0
Long-term Debt, Fair Value	[5]								1,548,656,000			1,592,184,000
Business Combination, Contingent Consideration, Liability									0	[6]		0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure									0			0
Foreign Currency Contract, Asset, Fair Value Disclosure									0	[3]		0
Foreign Currency Contracts, Liability, Fair Value Disclosure									0	[3]		0
Investments, Fair Value Disclosure									0	[4]		0
Deferred Compensation Plan Assets, Fair Value									0	[4]		0
Long-term Debt, Fair Value	[5]								0			0
Business Combination, Contingent Consideration, Liability	[6]								7,420,000			5,886,000
Capital Additions [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability					2,348,000
Reductions and Payout [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability					(182,000)
Foreign Currency Gain (Loss) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability					(632,000)
Cost of Sales [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Gain (Loss) on Sale of Commodity Contracts		$ 205,000		$ (288,000)	$ 416,000	$ (333,000)
United Kingdom, Pounds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability, Notional Amount | £								£ 7,000
Euro Member Countries, Euro
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability, Notional Amount | €											€ 3,000
Switzerland, Francs
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability, Notional Amount | MXN							MXN 65,000
Equity Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale Securities, Amortized Cost Basis									11,037,000			4,681,000
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax	[1]								0			0
Available-for-sale Equity Securities, Accumulated Gross Unrealized Loss, before Tax	[1]								(918,000)			(185,000)
Investments, Fair Value Disclosure									10,119,000			4,496,000
Mutual Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale Securities, Amortized Cost Basis									1,187,000			1,289,000
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax	[1]								462,000			407,000
Available-for-sale Equity Securities, Accumulated Gross Unrealized Loss, before Tax	[1]								0			0
Investments, Fair Value Disclosure									1,649,000			1,696,000
Carrying (Reported) Amount, Fair Value Disclosure [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[2]								254,351,000			248,841,000
Foreign Currency Contract, Asset, Fair Value Disclosure	[3]								405,000			145,000
Foreign Currency Contracts, Liability, Fair Value Disclosure	[3]								24,000			122,000
Investments, Fair Value Disclosure	[4]								11,768,000			6,192,000
Deferred Compensation Plan Assets, Fair Value	[4]								1,735,000			1,765,000
Long-term Debt, Fair Value	[5]								1,504,192,000			1,567,796,000
Business Combination, Contingent Consideration, Liability	[6]								$ 7,420,000			$ 5,886,000
[1]	Amounts reported include the impact of foreign currency movements relative to the U.S. dollar.
[2]	(1) Money market fund holdings are classified as level two as active market quoted prices are not available.
[3]	(2) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates.
[4]	We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Changes in the value of the investment accounts are recognized each period based on the fair value of the underlying investments. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers including an incremental investment of $4,564 made in April 2016.
[5]	(4) We estimate the fair value of our principal amount of long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements.
[6]	(5) Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.

Reclassifications out of Accu54

Reclassifications out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016	Mar. 31, 2016
Reclassifications from AOCI [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax		$ (94,028)		$ (94,028)		$ (85,718)	$ (68,159)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax		26	$ (552)	(94)	$ (1,400)
Other Comprehensive Income (Loss), Net of Tax		(7,826)		(24,920)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		(484)		(949)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent		(8,310)	$ (5,591)	(25,869)	$ 7,206
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Reclassifications from AOCI [Line Items]
Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	[1]	(767)		(767)		(793)	(673)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	[1]	17		(131)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	[1]	9		37
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	[1]	26		(94)
Accumulated Defined Benefit Plans Adjustment [Member]
Reclassifications from AOCI [Line Items]
Accumulated Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net of Tax	[2]	4,328		4,328		4,718	5,108
Other Comprehensive Income (Loss), Net of Tax	[2]	103		206
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	[2]	(493)		(986)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	[2]	(390)		(780)
Accumulated Translation Adjustment [Member]
Reclassifications from AOCI [Line Items]
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax		(97,589)		(97,589)		$ (89,643)	$ (72,594)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax		(7,946)		(24,995)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		0		0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent		$ (7,946)		$ (24,995)
[1]	(1) Realized gain (loss) on available for sale securities is reported in the interest income and miscellaneous expense line of the Consolidated Statements of Income.
[2]	(2) Amortization (gain) of defined benefit pension items is reported in the selling, general and administrative expense line of the Consolidated Statements of Income. (3) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.